Blood conservation in practice: An overview

British Journal of Hospital Medicine

Volumn 70, Issue 1, 2009, Pages 16-21

  Shander, Aryeh ^b   Moskowitz, David M ^a   Javidroozi, Mazyar ^b  

^a Department of Cardiothoracic Anesthesia ^*

^b ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 64549109027     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2009.70.1.37689     Document Type: Conference Paper

References (29)

1. American Society of Anesthesiologists (1996) Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 84 (3) : 732-47
2. Bennett CL, Silver SM, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 (8) : 914-24
3. Carless PA, Henry DA, Moxey AJ, O'Connell DL, Brown T, Fergusson DA (2006) Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 4: CD001888
4. Clinical Excellence Commission (2008) Blood watch program. New South Wales Government, Sydney
5. Consensus Conference (1988) Perioperative red blood cell transfusion. JAMA 260 (18) : 2700-3
6. Fakhry SM, Fata P (2004) How low is too low? Cardiac risks with anemia. Crit Care 8 (Suppl 2) : S11-S14
7. Fergusson DA, Hébert PC, Mazer CD et al (2008) A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (22) : 2319-31
8. Ferraris VA, Ferraris SP, Saha SP et al (2007) Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 83 (5 Suppl) : S27-86
9. Food and Drug Administration (2008) Follow Up to the January 3, 2008 Communication About an Ongoing Safety Review Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp). US Food and Drug Administration, Rockville
10. Goodnough LT, Shander A (2007) Blood management. Arch Pathol Lab Med 131 (5) : 695-701
11. Goodnough LT, Shander A, Spence R (2003) Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 43 (5) : 668-76
12. Goodnough LT, Shander A, Spivak JL et al (2005) Detection, evaluation, and management of anemia in the elective surgical patient. Anesth Analg 101 (6) : 1858-61
13. Hébert PC, Wells G, Blajchman MA et al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340 (6) : 409-17
14. Hébert PC, Tinmouth A, Corwin HL (2007) Controversies in RBC transfusion in the critically ill. Chest 131 (5) : 1583-90
15. Henry DA, Carless PA, Moxey AJ et al (2007) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 4: CD001886
16. Hsia CC, Chin-Yee IH, McAlister VC (2008) Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 248 (1) : 61-8
17. Innes G (1998) Guidelines for red blood cells and plasma transfusion for adults and children: an emergency physician's overview of the 1997 Canadian blood transfusion guidelines. Part 1: red blood cell transfusion. Canadian Medical Association Expert Working Group. J Emerg Med 16 (1) : 129-31
18. Madjdpour C, Spahn DR, Weiskopf RB (2006) Anemia and perioperative red blood cell transfusion: a matter of tolerance. Crit Care Med 34 (5 Suppl) : S102-S108
19. Ranucci M, Isgro G, Soro G, Conri D, De Toffol B (2008) Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg 143 (3) : 296-304
20. Shander A (2004) Emerging risks and outcomes of blood transfusion in surgery. Semin Hematol 41 (1) (Suppl 1) : 117-24
21. Shander A, Goodnough LT (2006) Objectives and limitations of bloodless medical care. Curr Opin Hematol 13 (6) : 462-70
22. Shander A, Perelman S (2006) The long and winding road of acute normovolemic hemodilution. Transfusion 46 (7) : 1075-9
23. Shander A, Hofmann A, Gombotz H, Theusinger OM, Spahn DR (2007) Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 21 (02) : 271-89
24. Shaw AD, Stafford-Smith M, White WD et al (2008) The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358 (8) : 784-93
25. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110 (3) : 477-88
26. Vincent JL, Sakr Y, De Backer D, Van der Linden P (2007) Efficacy of allogeneic red blood cell transfusions. Best Pract Res Clin Anaesthesiol 21 (2) : 209-19
27. Voils S (2007) Pharmacologic interventions for the management of critical bleeding. Pharmacotherapy 27 (9) : 69S-84
28. von Heymann C, Jonas S, Spies C et al (2008) Recombinant activated factor Vila for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care 12 (1) : R14
29. Weiskopf RB (2001) Efficacy of acute normovolemic hemodilution assessed as a function of fraction of blood volume lost. Anesthesiol 94 (3) : 439-46